Welcome to the board. I have to disagree when you say that Kizmet Impact is central to Dr Dalton’s plans to uplist. Kizmet is involved in investing, building a portfolio of companies, a fund to say the least. Unless I missed it, I didn’t see where they are in the business of bringing startups to market or helping OTC companies come to a larger market like Nasdaq. Dr Dalton has aligned himself with investment companies, fund managers etc for the purpose imo of buying into Univec when it does hit Nasdaq or wherever at this point. One thing you might be correct on is 2022 being the year we actually uplist to Nasdaq. Dr Dalton said Q4, we’ll keep that in mind, but in the 3 years I have been in the stock, things have changed course many times without explanation from the company, explanation yes from shareholders but not the company. A month left in the year, 2022 is almost here if that’s any consolation. All in my opinion